Research programme: immune tolerance-inducing therapeutics - Anokion

Drug Profile

Research programme: immune tolerance-inducing therapeutics - Anokion

Alternative Names: Autoimmune disease therapeutics - Anokion; Cancer therapeutics - Anokion; Diabetes therapeutic - Anokion; Immune-masked protein theraputics - Anokion; Tolerogenic asparaginase - Anokion

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anokion
  • Class Antigens; Peptides; Proteins
  • Mechanism of Action Antigen-presenting-cell-modulators; Immunomodulators; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer
  • No development reported Gout

Most Recent Events

  • 09 Jan 2017 Anokion and Celgene enter into research collaboration for immune tolerance-inducing therapeutics for Autoimmune disorders
  • 16 Jul 2016 No recent reports of development identified for research development in Gout in Switzerland (IV)
  • 05 May 2014 Research programme: immune tolerance-inducing therapeutics - Anokion is available for licensing as of 05 May 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top